PDE4 inhibitor Roflumilast is FDA-approved for treating severe chronic obstructive pulmonary disease (COPD) [25], but the specific role of PDE10A in NLRP3 inflammasome activation remains unclear. Here, PDE10A is linked to chronic obstructive pulmonary disease.